Anixa Biosciences (ANIX) Payables (2010 - 2026)

Anixa Biosciences (ANIX) has reported Payables for 17 consecutive years, with $252000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 11.27% year-over-year to $252000.0; the trailing twelve-month figure through Apr 2026 stood at $252000.0 (down 11.27% YoY), and the FY2025 full-year result was $165000.0, down 68.57% from the prior year.
• Payables advanced to $252000.0 in Q2 2026 per ANIX's latest filing, from $165000.0 in the prior quarter.
• Across five years, Payables topped out at $600000.0 in Q1 2025 and bottomed at $93000.0 in Q2 2022.
• Historically, Payables has averaged $275117.6 across 5 years, with a median of $252000.0 in 2026.
• The sharpest annual moves came in 2022 and 2024: Payables tumbled 78.77% in 2022, then jumped 230.91% in 2024.
• Over 5 years, Payables stood at $265000.0 in 2022, then decreased by 22.26% to $206000.0 in 2023, then surged by 154.85% to $525000.0 in 2024, then tumbled by 68.57% to $165000.0 in 2025, then jumped by 52.73% to $252000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $252000.0, $165000.0, and $276000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.